Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

Published:2017-04 Issue:4 Volume:28 Page:761-768
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Swain S.M.,Schneeweiss A.,Gianni L.,Gao J.J.,Stein A.,Waldron-Lynch M.,Heeson S.,Beattie M.S.,Yoo B.,Cortes J.,Baselga J.

Funder

National Institutes of Health

Genentech, Inc

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference14 articles.

1. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex;Franklin;Cancer Cell,2004

2. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth;Agus;Cancer Cell,2002

3. ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: chloride secretion as a mechanistic hypothesis;Van Sebille;Cancer Treat Rev,2015

4. Supportive care treatments for toxicities of anti-egfr and other targeted agents;Melosky;Curr Oncol,2012

5. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies;Gibson;Support Care Cancer,2006

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Trastuzumab Combined with Pertuzumab for Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer: A Meta-Analysis Study of Randomized Control Trials;Journal of Clinical Pharmacy and Therapeutics;2023-12-12

2. Breast Cancer;Side Effects of Cancer Therapy;2023-11-23

3. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial;BMJ;2023-10-31

4. A Unique Endoscopic Presentation of Colon Metastases From Primary Invasive Lobular Carcinoma of the Breast;Cureus;2023-04-20

5. HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane;Breast Cancer Research and Treatment;2022-10-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3